SBMU, Pharmaceutical Research Sciences
  • Register
  • Login
International Pharmacy Acta
  • Home
  • Journal Info
    • About
    • Aim and Scope
    • Ownership & Management
    • Indexing
    • Editorial Team
  • New Submission
  • Author Guidelines
    • Guideline
    • Types of articles
    • Templates
    • Publication Fees
  • Policies and Process
    • Publication Policy
    • Peer Review Process
    • Open Access Policy
    • plagiarism
    • Archiving
    • Privacy Statement
    • Copyright Notice
    • Waiver policy
    • Complaints Policy
    • Post- Publication Discussions and Corrections Policy
    • Advertisement and Marketing
  • Issues
    • Current
    • Archives
  • Contact us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 1 No. 1 (2018): Pharmacy Updates 2018 (Congress Proceeding)
  4. Supplementary Issues: Reviews of books, journal, congress, other media Special issues, and Scientific news

Vol. 1 No. 1 (2018)

March 2018

The effect of berberine nanomicells on hepatic cirrhosis in bile duct ligated rats

  • Seyed Pouyan Pishva
  • Seyyedeh Elaheh Mousavi
  • Zahra Mousavi
  • Mahmood Reza Jaafari
  • Ahmad Reza Dehpour
  • Seyed Mahdi Rezayat Sorkhabadi

International Pharmacy Acta, Vol. 1 No. 1 (2018), 4 March 2018 , Page 146-146
https://doi.org/10.22037/ipa.v1i1.20455 Published: 2018-03-04

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

The present study was designed to investigate the possible hepatoprotective effect of berberine (BBR) nano micelles on liver cirrhosis induced by bile duct ligation model (BDL) in male rats.

Introduction: The anti-fibrotic effect of chronic berberine (BBR) had previously demonstrated in a rat model of bile duct ligation (BDL) - induced liver fibrosis. As a result, the aim of present study was to investigate the possible hepatoprotective effect of BBR nanomicelles on liver cirrhosis induced by Bile duct ligation model (BDL) in male rats.

Methods and Results: Male Wistar rats were divided into 7 groups (n= 6) including sham-operated, BDL + saline, BDL + nanoBBR (50 mg/kg, p.o.), BDL + nanomicelles, BDL + BBR (50 and 100 mg/kg, p.o.), BDL + silymarin (100 mg/kg, p.o.). After 21 days of drugs' treatments following bile duct ligateation, the serum and tissue levels of some hepatic markers were measured and pathologic evaluations performed.BDL could markedly increase aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL) serum levels and tissue tumor necrosis factor-alpha (TNF-α), level along with reductions in tissue levels of glutathione (GSH), superoxide dismutase (SOD) and total protein levels. On the other hand, BBR nanomicelles (50 mg/kg, p.o.) and silymarin (100 mg/kg, p.o.) markedly decreased the serum levels of AST and ALT while enhanced GSH level. In addition, BBR nanomicelles (50 mg/kg, p.o.), silymarin (100 mg/kg, p.o.) and BBR (100 mg/kg, p.o.) groups showed a considerable increase in SOD levels. BBR nanomicelles (50 mg/kg, p.o.) significantly lowered TNF-α level. In addition, nanoBBR group prevented liver cirrhosis in histopathologic analysis.

 Conclusions:Therefore, formulation of BBR nanomicelles may represent a good approach to enhance the effect of BBR in liver injuries.

Keywords:
  • Bile duct ligation; nanoberberin; berberin; hepatoprotection; oxidative stress; Rat
  • PDF

How to Cite

Pishva, S. P., Mousavi, S. E., Mousavi, Z., Jaafari, M. R., Dehpour, A. R., & Rezayat Sorkhabadi, S. M. (2018). The effect of berberine nanomicells on hepatic cirrhosis in bile duct ligated rats. International Pharmacy Acta, 1(1), 146–146. https://doi.org/10.22037/ipa.v1i1.20455
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 356 times
  • PDF Downloaded: 164 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Make a Submission

Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a  Creative Commons Attribution-NonCommercial 4.0 International License.

 

                                                  Online ISSN: 2645-3266

                                                  Print ISSN: 2645-3258                                                 

Powered by OJSPlus